$SYK

Stryker (SYK) shares fell $26.70 (-8.8%) on Sept. 8, 2026, after its CFO revealed persisting manufacturing issues in its Peripheral Vascular unit, acquired from Inari Medical. The firm Hagens Berman is investigating potential disclosure violations. The issue, initially thought resolved, led to lost sales and backorders, with the CFO stating it will continue into Q4.

Morningstar identified 30 US-listed stocks as newly undervalued, including ServiceNow (NOW), Booking Holdings (BKNG), British American Tobacco (BTI), Stryker (SYK), and General Dynamics (GD). These stocks now have a 4-star rating, with prices below their fair value estimates. The US stock market is moderately undervalued, according to Morningstar.

Stryker (NYSE) agreed to acquire ZuriMED, a private Swiss developer of rotator cuff augmentation tech. The deal aims to bolster Stryker's shoulder care portfolio, addressing a key clinical need. ZuriMED was spun off from Swiss universities in 2015.

Bonesupport has partnered with Stryker to distribute its products in Australia and New Zealand, with the transition set for Q4 2026. Stryker, a global leader in medical technology, reported 2025 sales of $18.2 billion, with 75.7% from the US and 37.7% from orthopedic implants.

Stryker (SYK) VP and Corporate Controller Emily Kay Baculik reported initial holdings of 5,538 stock options and 1,554 shares of common stock, including 20 shares indirectly. Options were granted under the 2011 Long-Term Incentive Plan, exercisable in 20% increments over five years, with exercise prices ranging from $248.60 to $392.39 and expirations between 2032 and 2036.

Boston Scientific and Stryker report ongoing disruptions from cyberattacks, impacting operations and financial projections. Boston Scientific expects to miss Q3 and full-year revenue and EPS targets, with recovery timelines unclear. Stryker's CFO noted longer-than-expected recovery times for manufacturing. Both companies are major players in medical technology, and the incidents highlight cyber risks in the sector.

The FBI is collaborating with private sector and international allies to combat Iranian cyber attacks on US digital infrastructure. Officials warn of increasing AI-driven threats and emphasize shared intelligence. Recent attacks include breaches at Stryker and California Water Service, with Iran-linked group Handala claiming responsibility.

Stryker (-7%) faces supply constraints; Amgen (-10%) slides after Novartis' drug trial results. Qualcomm (+4%) partners with AWS. AI-linked stocks surge: CoreWeave (+15%), Lumentum (+12%), Coherent (+9%). Travel stocks fall as gasoline futures rise. Roivant (+20%) reports positive trial results. Lockheed (+3%) upgraded by UBS. Novartis (-13%) faces third drug-trial setback. Peloton (-5%) downgraded by Morgan Stanley. Boston Scientific (-5%) hit by cyberattack. Bloom Energy (+10%) set to join S&P

Stryker Corporation (SYK) hit a 52-week low after its CFO highlighted challenges in the vascular segment. GF Value™ estimates SYK is 33.5% undervalued at $277.60, with a GF Score™ of 94. Insider selling totaled $586.1M over 12 months, while 11 gurus have mixed positions. SYK's P/E ratio is 28.77x, below its 5-year median of 42.11x.

Stryker (SYK) shares fell 6.9% after management at a healthcare conference indicated longer-than-expected supply chain issues and slower joint replacement recovery, potentially affecting revenue. The company had reported solid Q2 results in July. Insider sales and mixed hedge fund activity were also noted.